CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Voxilaprevirdrug
Likely dose
Voxilaprevir 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02402452
NCT02402452Phase 1Completed
CompareCT.gov

A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Renal Function and Severe Renal Impairment

Gilead Sciences·interventional·Posted Mar 30, 2015·Updated Mar 20, 2020

In Brief

A Phase 1 clinical trial evaluating Voxilaprevir for HCV Infection. Completed, enrolled 20 participants across 4 sites in 3 countries.

Detailed Summary

The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHCV Infection
CountriesGermany, New Zealand, United States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 30, 2015
Enrollment StartMay 5, 2015
Primary CompletionSep 28, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.3 years ago

Interventions

Voxilaprevirdrug

100 mg tablet administered orally